TAIZ -Monocytes for the Induction of Donor Specific Tolerance in Renal Allograft Recipients (Cadaver Kidney)
Phase 1
- Conditions
- Renal Transplantation
- Registration Number
- NCT00223093
- Lead Sponsor
- University Hospital Schleswig-Holstein
- Brief Summary
Induce tolerance or reduce the amount of immunosuppression after renal transplant patient (receiving cadaver kidney)with so called TAIZ-monocytes
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method graft survival replacement of immunosuppressives after treatment with Transplant-Acceptance Inducing Cells (TAIC) serum creatinine rejection episodes re-introduction of immunosuppressives.
- Secondary Outcome Measures
Name Time Method safety and tolerability of the treatment with Transplant-Acceptance Inducing Cells (TAIC) Adverse Events (AEs)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which TAIZ-monocytes induce donor-specific tolerance in renal allograft recipients?
How does TAIZ-monocyte therapy compare to standard immunosuppressive regimens in cadaver kidney transplant outcomes?
Which biomarkers correlate with successful donor-specific tolerance induction using TAIZ-monocytes in renal transplant patients?
What adverse events are associated with TAIZ-monocyte administration in renal allograft recipients and how are they managed?
Are there combination therapies or alternative approaches to TAIZ-monocytes for donor-specific tolerance in renal transplantation?